North America Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Country and Growth Forecast, 2024 - 2031
North America Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Country and Growth Forecast, 2024 - 2031
The North America Diabetic Neuropathy Treatment Market would witness market growth of 6.6% CAGR during the forecast period (2024-2031).
The US market dominated the North America Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $1,993 million by 2031. The Canada market is experiencing a CAGR of 9% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 8.1% during (2024 - 2031).
An area of notable progress in the management of diabetic neuropathy pertains to the creation of innovative pharmacological interventions. Several medications have been approved for this purpose, including anticonvulsants, antidepressants, and opioids.
Additionally, these approaches include physical therapy, occupational therapy, and lifestyle modifications such as diet and exercise. The primary objectives are to enhance muscular strength and flexibility, alleviate pain and discomfort, and elevate the quality of life for those afflicted with diabetic neuropathy.
According to the National Library of Medicine, diabetes mellitus is particularly significant in Mexico, where it ranks as the sixth highest for the number of adults affected, with 12.8 million individuals diagnosed with the disease in 2019. This number is projected to rise significantly, reaching an estimated 22.3 million by the year 2045. The Mexican government implemented a program (El Sistema de Vigilancia Epidemiológica Hospitalaria de Diabetes Mellitus Tipo 2, SVEHDMT2) to monitor hospital attendance by people suffering from type 2 diabetes mellitus.
Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy.Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
List of Key Companies Profiled
Abbott Laboratories
Eli Lilly And Company
Pfizer, Inc.
Lupin Limited
Astellas Pharma, Inc.
Glenmark Pharmaceuticals Limited
Boehringer Ingelheim International GmbH
Novartis AG
McKesson Corporation
GlaxoSmithKline PLC (GSK)
North America Diabetic Neuropathy Treatment Market Report Segmentation
By Distribution Channel
Hospitals Pharmacies
Retail Pharmacies
Others
By Drug Class
Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
Antidepressants
Opioid
Capsaicin
Others
By Disorder Type
Peripheral Neuropathy
Autonomic Neuropathy
Proximal Neuropathy
Focal Neuropathy
By Country
US
Canada
Mexico
Rest of North America
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Diabetic Neuropathy Treatment Market, by Distribution Channel
1.4.2 North America Diabetic Neuropathy Treatment Market, by Drug Class
1.4.3 North America Diabetic Neuropathy Treatment Market, by Disorder Type
1.4.4 North America Diabetic Neuropathy Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. North America Diabetic Neuropathy Treatment Market by Distribution Channel
4.1 North America Hospitals Pharmacies Market by Country
4.2 North America Retail Pharmacies Market by Country
4.3 North America Others Market by Country
Chapter 5. North America Diabetic Neuropathy Treatment Market by Drug Class
5.1 North America Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
5.2 North America Antidepressants Market by Country
5.3 North America Opioid Market by Country
5.4 North America Capsaicin Market by Country
5.5 North America Others Market by Country
Chapter 6. North America Diabetic Neuropathy Treatment Market by Disorder Type
6.1 North America Peripheral Neuropathy Market by Country
6.2 North America Autonomic Neuropathy Market by Country
6.3 North America Proximal Neuropathy Market by Country
6.4 North America Focal Neuropathy Market by Country
Chapter 7. North America Diabetic Neuropathy Treatment Market by Country
7.1 US Diabetic Neuropathy Treatment Market
7.1.1 US Diabetic Neuropathy Treatment Market by Distribution Channel
7.1.2 US Diabetic Neuropathy Treatment Market by Drug Class
7.1.3 US Diabetic Neuropathy Treatment Market by Disorder Type
7.2 Canada Diabetic Neuropathy Treatment Market
7.2.1 Canada Diabetic Neuropathy Treatment Market by Distribution Channel
7.2.2 Canada Diabetic Neuropathy Treatment Market by Drug Class
7.2.3 Canada Diabetic Neuropathy Treatment Market by Disorder Type
7.3 Mexico Diabetic Neuropathy Treatment Market
7.3.1 Mexico Diabetic Neuropathy Treatment Market by Distribution Channel
7.3.2 Mexico Diabetic Neuropathy Treatment Market by Drug Class
7.3.3 Mexico Diabetic Neuropathy Treatment Market by Disorder Type
7.4 Rest of North America Diabetic Neuropathy Treatment Market
7.4.1 Rest of North America Diabetic Neuropathy Treatment Market by Distribution Channel
7.4.2 Rest of North America Diabetic Neuropathy Treatment Market by Drug Class
7.4.3 Rest of North America Diabetic Neuropathy Treatment Market by Disorder Type